Grape King Bio logo

1707 - Grape King Bio Share Price

TWD168.5 1.5  0.9%

Last Trade - 6:30am

Sector
Consumer Defensives
Size
Mid Cap
Market Cap £610.0m
Enterprise Value £633.3m
Revenue £243.9m
Position in Universe 955th / 5933
Bullish
Bearish
Unlock 1707 Revenue
Momentum
Relative Strength (%)
1m -7.92%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -28.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
6,283 7,248 9,185 9,388 9,183 9,239 9,414 10,140 +8.0%
+12.7 +9.8 +21.1 +4.1 -4.5 +0.8 +4.15 +8.55
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Grape KingBio Ltd revenues decreased 4% to NT$4.26B. Net incomedecreased 5% to NT$547.5M. Revenues reflect OEM Departmentsegment decrease of 21% to NT$443.8M, Direct Sales segmentdecrease of 2% to NT$3.57B. Basic Earnings per Shareexcluding Extraordinary Items decreased from NT$4.25 toNT$4.02.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 1707
Graphical History

Revenue

1707 Revenue Unlock 1707 Revenue

Net Income

1707 Net Income Unlock 1707 Revenue

Normalised EPS

1707 Normalised EPS Unlock 1707 Revenue

PE Ratio Range

1707 PE Ratio Range Unlock 1707 Revenue

Dividend Yield Range

1707 Dividend Yield Range Unlock 1707 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
1707 EPS Forecasts Unlock 1707 Revenue
Profile Summary

Grape King Bio Ltd is a Taiwan-based company mainly engaged in the manufacture and sale of healthcare products and beverages. The company operates through three business segments. The Direct Sales segment is engaged in the development and manufacture of related products for subsidiaries. The Distribution segment is engaged in the provision of own-brand products. The Original Equipment Manufacturer (OEM) segment is engaged in the OEM business in Taiwan and Shanghai. The main products include lactic acid bacteria products and other healthcare products, as well as beverage products, medicines and cosmetics. The Company operates in Taiwan, mainland China and other markets.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated April 1, 1971
Public Since December 20, 1982
No. of Shareholders: 30,958
No. of Employees: 501
Sector Consumer Defensives
Industry Food & Tobacco
Index Taiwan SE Weighted ,
Exchange Taiwan Stock Exchange
Shares in Issue 136,032,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
1707 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 1707
Upcoming Events for 1707
Frequently Asked Questions for Grape King Bio
What is the Grape King Bio share price?

As of 6:30am, shares in Grape King Bio are trading at TWD168.5, giving the company a market capitalisation of £610.0m. This share price information is delayed by 15 minutes.

How has the Grape King Bio share price performed this year?

Shares in Grape King Bio are currently trading at TWD168.5 and the price has moved by -11.41% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Grape King Bio price has moved by -11.43% over the past year.

What are the analyst and broker recommendations for Grape King Bio?

Of the analysts with advisory recommendations for Grape King Bio, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Grape King Bio is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Grape King Bio next release its financial results?

Grape King Bio is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Grape King Bio dividend yield?

The Grape King Bio dividend yield is 3.89% based on the trailing twelve month period.

Does Grape King Bio pay a dividend?

Last year, Grape King Bio paid a total dividend of 6.5, and it currently has a trailing dividend yield of 3.89%. Looking ahead, Grape King Bio has not announced an ex-dividend date yet.

When does Grape King Bio next pay dividends?

Grape King Bio has yet to annouce their ex-dividend date. The historic dividend yield on Grape King Bio shares is currently 3.89%.

How do I buy Grape King Bio shares?

To buy shares in Grape King Bio you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Grape King Bio?

Shares in Grape King Bio are currently trading at TWD168.5, giving the company a market capitalisation of £610.0m.

Where are Grape King Bio shares listed? Where are Grape King Bio shares listed?

Here are the trading details for Grape King Bio:

Country of listing: Taiwan
Exchange: TAI
Ticker Symbol: 1707
What kind of share is Grape King Bio?

Based on an overall assessment of its quality, value and momentum, Grape King Bio is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Grape King Bio share price forecast 2020?

Shares in Grape King Bio are currently priced at TWD168.5. At that level they are trading at 34.61% discount to the analyst consensus target price of 0.00.

Analysts covering Grape King Bio currently have a consensus Earnings Per Share (EPS) forecast of 9.987 for the next financial year.

How can I tell whether the Grape King Bio share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Grape King Bio. Over the past six months, the relative strength of its shares against the market has been -28.97%. At the current price of TWD168.5, shares in Grape King Bio are trading at -12.11% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Grape King Bio PE Ratio?

The Grape King Bio PE ratio based on its reported earnings over the past 12 months is 17.82. The shares are currently trading at TWD168.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Grape King Bio?

Grape King Bio's management team is headed by:

Sheng-Bin Tseng - DRC
Andrew Tseng - CHM
Zhijia Chang - DRC
Nick Hung - CFO
Jin-Chu Chen - DGM
Mei-Ching Tseng - DRC
Zhiwei Lai - DRC
Yanxiang Huang - DRC
Yuan-Tsung Lin - DGM
Chih-Lin Hung - OTH
Who are the major shareholders of Grape King Bio?

Here are the top five shareholders of Grape King Bio based on the size of their shareholding:

Fubon Life Insurance Co., Ltd. Insurance Company
Percentage owned: 6.6% (9.00m shares)
Nan Shan Life Insurance Co., Ltd. Insurance Company
Percentage owned: 4.91% (6.69m shares)
Tseng (Sheng Lin) Individual Investor
Percentage owned: 4.66% (6.35m shares)
Tseng (Mei Ching) Individual Investor
Percentage owned: 3.66% (4.99m shares)
Cathay Life Insurance Co., Ltd. Insurance Company
Percentage owned: 3.15% (4.29m shares)
Similar to 1707
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.